tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ASKA Pharmaceutical Expands Southeast Asian Presence with Hataphar Acquisition

Story Highlights
ASKA Pharmaceutical Expands Southeast Asian Presence with Hataphar Acquisition

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an announcement.

ASKA Pharmaceutical Co., Ltd. announced its decision to acquire additional shares of Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical firm, making it a consolidated subsidiary. This move aligns with ASKA’s Medium-Term Management Plan 2025 to enhance its presence in the rapidly growing Southeast Asian market and further its corporate value through strategic overseas expansion.

More about ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry with a focus on the production and sale of ethical pharmaceuticals, over-the-counter drugs, and health foods. The company is primarily engaged in the healthcare sector with a strong emphasis on obstetrics and gynecology, aiming to expand its business in Southeast Asia.

YTD Price Performance: -6.29%

Average Trading Volume: 58,094

Technical Sentiment Consensus Rating: Hold

Current Market Cap: Yen55.89B

For an in-depth examination of 4886 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1